跳至主要内容
临床试验/NCT00259766
NCT00259766已完成3 期

Symbicort and Health Economics in a Real Life Evaluation - SHARE - A Randomised, Open-Label, Parallel-Group, Multicentre Study to Assess the Asthma-Related Health-Care Costs, in Ordinary Clinical Practice During 12 Months

AstraZeneca108 个研究点 分布在 1 个国家目标入组 1,970 人开始时间: 2004年4月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
AstraZeneca
入组人数
1,970
试验地点
108
主要终点
Asthma-related health-care utilization as measured by total amount of asthma medication purchased and number of contacts with health-care facilities

研究概览

简要总结

The purpose of this study is to compare health-related costs and asthma control in ordinary clinical practice during 12 months for Symbicort® given as a low maintenance dose plus as needed compared to a free combination of Pulmicortâ and Oxis® plus Bricanyl® as needed, and Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately controlled on inhaled glucocorticosteroids alone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
12 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent,
  • previously treated with glucocorticosteroids and B2-agonist

排除标准

  • History of smoking, pregnancy, any significant disease or disorder which may put the patient at risk because of study participation

结局指标

主要结局

Asthma-related health-care utilization as measured by total amount of asthma medication purchased and number of contacts with health-care facilities

次要结局

  • Number of days patients or assistant persons are absent from work due to patient's asthma
  • Number of exacerbations and treatment failures

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (108)

Loading locations...

相似试验